4D Molecular director granted 50,000 stock options
4D Molecular Therapeutics director Susannah Gray received a grant of stock options for 50,000 shares of common stock.
Rhea-AI Filing Summary
4D Molecular Therapeutics director Susannah Gray received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036. One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, as long as she continues serving the company. The options were automatically granted under the non-employee director compensation program, and this grant brings her direct option holdings reported in this filing to 50,000 shares.
Insider Trade Summary
Grant/Award: 50,000 shares
Grant/Award
1 txn
Insider
GRAY SUSANNAH
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 contracts (Direct)
Footnotes (2)
- F1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- F2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Key Figures
Option grant size: 50,000 shares
Exercise price: $9.42 per share
Total options after grant: 50,000 shares
+3 more
6 metrics
Option grant size
50,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$9.42 per share
Exercise price of newly granted options
Total options after grant
50,000 shares
Total derivative securities following transaction
Option expiration date
June 16, 2036
Expiration of the stock option grant
Initial vesting date
June 17, 2027
1/3 of options vest on this date
Final vesting date
June 17, 2029
Options fully vested by this date
Key Terms
Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
non-employee director compensation program financial
"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."
Change in Control financial
"Additionally, the stock options will vest in full upon the consummation of a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2020 Incentive Award Plan financial
"Change in Control (as defined in the 2020 Incentive Award Plan)."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FDMT director Susannah Gray report in this Form 4 filing?
FDMT director Susannah Gray reported receiving a grant of stock options for 50,000 shares of common stock. These options were automatically issued under the company’s non-employee director compensation program as part of her board service compensation package.
What is the exercise price of Susannah Gray’s new 4D Molecular FDMT stock options?
The newly granted FDMT stock options have an exercise price of $9.42 per share. This is the price per share Gray must pay to purchase common stock if and when she chooses to exercise the options in the future.
How do the 50,000 FDMT stock options granted to Susannah Gray vest over time?
One-third of Gray’s 50,000 FDMT stock options vest on June 17, 2027. The remaining options vest in equal monthly installments thereafter, fully vesting on June 17, 2029, contingent on her continued service to 4D Molecular Therapeutics.
When do Susannah Gray’s FDMT stock options expire if not exercised?
The options granted to Gray expire on June 16, 2036, if not exercised before that date. After expiration, she would no longer be able to purchase FDMT common stock under this particular stock option grant.
Under what program were the FDMT stock options granted to Susannah Gray?
The FDMT stock options were automatically granted under 4D Molecular Therapeutics’ non-employee director compensation program. The grant is made pursuant to the company’s 2020 Incentive Award Plan, which governs the terms and conditions of these equity awards.
Do Susannah Gray’s FDMT stock options have any special vesting provisions on a change in control?
Yes. The filing states that Gray’s FDMT stock options will vest in full upon the consummation of a Change in Control, as defined in the company’s 2020 Incentive Award Plan, regardless of the regular time-based vesting schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
